Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Parkinson Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UAB, Birmingham, Alabama, United States
Contact: Study coordinator (Evan Hudson, BS) · evanhudson@uabmc.edu · 205-934-6499
Contact: Principal Investigator (Jonathan McConathy, MD,PhD)

Study leads

Jonathan McConathy, MD, PhD
Principal Investigator
University of Alabama at Birmingham
David Standaert, MD, PhD
Study Director
University of Alabama at Birmingham

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

Parkinson Disease

Abroad (travel likely)RecruitingPHASE1

Darlinghurst, Australia · Kogarah, Australia

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Parkinson Disease Psychosis · Amyotrophic Lateral Sclerosis (ALS)

Abroad (travel likely)RecruitingPHASE1

Seoul, South Korea

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Parkinson Disease

Abroad (travel likely)RecruitingPHASE2

Davie, United States · Hialeah, United States

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Parkinson Disease

Abroad (travel likely)Recruiting

Ann Arbor, United States